Astellas Pharma Inc.-Unsp ADRALPMY
13F holders, Q2 2025 (June 30)8holders +4
4new positions
0sold out
$9.76avg. 13F price*
At the end of Q2 2025, 8 institutions reported holding Astellas Pharma Inc.-Unsp ADR (ALPMY) in their 13F filings, up 4 from Q1 2025. 4 opened new positions and 0 sold out. The largest holders were Hantz Financial Services, Inc. ($1.6M), Lanark Financial, Inc. ($436K) and Rhumbline Advisers ($304K).
- Company
- Astellas Pharma Inc.-Unsp ADR
- CUSIP
- 04623U102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $460K |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 52,748 shares bought and 2,736 shares sold, net +50,012 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Hantz Financial Services, Inc. | 0.03% | Add +2.1% | 165,304 | $1.6M |
| Lanark Financial, Inc. | 0.04% | New | 44,542 | $436K |
| Rhumbline Advisers | 0.00% | Reduce -8.1% | 31,138 | $304K |
| GAMMA Investing LLC | 0.00% | Add +47.7% | 7,172 | $70K |
| Brooklyn Investment Group | 0.00% | New | 2,229 | $22K |
| Wealth Preservation Advisors, LLC | 0.00% | New | 224 | $2K |
| PNC Financial Services Group, Inc. | 0.00% | Reduce -1.8% | 56 | $546 |
| Salomon & Ludwin, LLC | 0.00% | New | 18 | $174 |
"% of holder's portfolio" is ALPMY's weight in each manager's 13F, not the share of Astellas Pharma Inc.-Unsp ADR the manager owns.